REG - Intelligent Ultrasnd - SonoLystlive now standard on Voluson Expert Series

Intelligent UltrasoundAnnouncement

17/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231117:nRSQ7431Ta&default-theme=true

RNS Number : 7431T  Intelligent Ultrasound Group PLC  17 November 2023

SonoLystlive, powered by Intelligent Ultrasound's ScanNav AI, now standard on
the new GE HealthCare Voluson Expert Series 22 and 20 ultrasound machines

 

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces that GE HealthCare's SonoLystlive software, that is
powered by Intelligent Ultrasound's ScanNav AI, is now a standard feature on
its latest versions of the Voluson Expert Series portfolio of ultrasound
machines, the Expert 22 and Expert 20.

 

Powered by Intelligent Ultrasound's ScanNav AI software, SonoLystlive takes
ultrasound image recognition to the next level by automatically capturing
images in real time, as the clinician scans a mid-trimester patient. Using
practice guidelines from the International Society of Ultrasound in Obstetrics
and Gynecology (ISUOG), the AI software automatically recognises the anatomy,
captures the image and checks it off the list of required views. By minimising
the need to manually freeze, annotate and store images, the software
significantly reduces keystrokes and exam time for sonographers.

 

This new technology further builds on Intelligent Ultrasound's long-term
partnership agreement with GE HealthCare, which also incorporates Intelligent
Ultrasound's AI technology as an option add-on in its SonoLyst X/IR software
on the Voluson SWIFT ultrasound machine.

 

It is currently too early to fully assess the impact on the Company's 2024
clinical AI revenue forecasts of SonoLystlive moving from an option upgrade --
with a higher reward, but higher risk of uptake -- to a more predictable
revenue stream.

 

Stuart Gall, CEO of Intelligent Ultrasound, commented: "We are delighted that,
by incorporating SonoLystlive as a standard feature onto its Voluson Expert 22
and 20 ultrasound machine GE HealthCare is leading the way in using AI
software to improve obstetric workflows for the benefit of clinicians and
patients. The Voluson Expert Series is a market-leading ultrasound machine in
the global women's healthcare obstetrics market and SonoLystlive is a
fantastic example of how AI software can help save scanning time, whilst
de-stressing the scanning environment for the sonographer.

 

We remain excited that our novel 'classroom-to-clinic' approach is making
clinical diagnostic ultrasound easier to learn and simpler to use."

 

This announcement contains inside information for the purposes of the UK
version of Article 7 of Regulation (EU) 596/2014.

 

 

 

ENDS

 

Enquiries:

 

 Intelligent Ultrasound Group plc   www.intelligentultrasound.com (http://www.intelligentultrasound.com)
 Stuart Gall, CEO                   Tel: +44 (0)29 2075 6534
 Helen Jones, CFO

 Cavendish Securities Plc

 (Nominated advisor and broker)
 Giles Balleny (Corporate Finance)  Tel: +44 (0)20 7397 8900

 Dale Bellis (Sales)

 

  TB Cardew - PR Advisors   Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)

  Ed Orlebar                Tel: +44 (0)7738 724630
  Allison Connolly                                                    Tel: +44 (0)7587 453955
  Emma Pascoe-Watson                                                  Tel: +44 (0)7774 620415
  Jessica Pilling                                                     Tel: +44 (0)7918 584573

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,500 simulators have been sold to over 750 medical
institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA, but is not available for sale in any other territory requiring government
approval for this type of product.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBFBFTMTIBBJJ